Chemotherapy for advanced non-small-cell lung cancer.

[1]  W. Bezwoda,et al.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Smith.  Palliative chemotherapy for advanced non-small cell lung cancer , 1994, British medical journal.

[3]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Oxman,et al.  Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Liu Rj.  Chemotherapy outcomes in advanced non-small-cell lung carcinoma. , 1993 .

[6]  W. Evans.  Rationale for the treatment of non-small cell lung cancer , 1993 .

[7]  M. Cullen.  The MIC regimen in non-small cell lung cancer , 1993 .

[8]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[9]  M. Green,et al.  Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G Cartei,et al.  Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[11]  D. Johnson.  Chemotherapy for metastatic non-small-cell lung cancer--can that dog hunt? , 1993, Journal of the National Cancer Institute.

[12]  M. Cullen.  Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer. , 1993, Oncology.

[13]  R. Winn,et al.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[14]  T Anderson,et al.  Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. , 1993, Journal of the National Cancer Institute.

[15]  R. Stephens,et al.  The impact of clinical trials on the treatment of lung cancer. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  Cisplatin-mitomycin and vindesine in the treatment of inoperable non-small cell lung cancer groupe français de pneumo-cancérologie (GFPC) , 1993, European journal of cancer.

[17]  M. Fukuoka,et al.  CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Machin,et al.  A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. , 1992, British Journal of Cancer.

[19]  D. Talbot,et al.  New perspectives in lung cancer.5. New drugs in lung cancer. , 1992, Thorax.

[20]  M. Fukuoka,et al.  Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer : a phase II study , 1992 .

[21]  P. Bunn.  Clinical experiences with carboplatin (paraplatin) in lung cancer. , 1992, Seminars in oncology.

[22]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Pannuti,et al.  Activity of high-dose epirubicin in advanced non-small cell lung cancer. , 1991, European journal of cancer.

[24]  M. Riggi,et al.  Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques). , 1991, European journal of cancer.

[25]  M. Fukuoka,et al.  A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung carcinoma , 1991, Cancer.

[26]  F. Guidi,et al.  A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Crowley,et al.  A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Hatlevoll,et al.  Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer , 1991, Cancer.

[29]  T. Splinter.  Response rate as criterium to evaluate chemotherapy in non-small cell lung cancer , 1991 .

[30]  E. Lemarié,et al.  A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer , 1991, American journal of clinical oncology.

[31]  Paul A. BunnJr..  The Role of Systemic Chemotherapy in Non-Small Cell Lung Cancer , 1991 .

[32]  P. Warde,et al.  Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Cavalli,et al.  Combination chemotherapy with mitomycin, vindesine, and cisplatin for non‐small cell lung cancer association of antitumor activity with initial tumor burden and treatment center , 1990, Cancer.

[34]  J. Carles,et al.  A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer , 1990, Cancer.

[35]  C. Williams,et al.  A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. , 1990, British Journal of Cancer.

[36]  D. Finkelstein,et al.  Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  I. Smith,et al.  Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. , 1989, British Journal of Cancer.

[38]  P. Bunn.  The expanding role of cisplatin in the treatment of non-small-cell lung cancer. , 1989, Seminars in oncology.

[39]  R. Figlin,et al.  Supportive care versus supportive care and combination chemotherapy in metastatic non‐small cell lung cancer. Does chemotherapy make a difference? , 1989, Cancer.

[40]  R. Rosell,et al.  Quality of life during chemotherapy in non-small cell lung cancer patients. , 1989, Acta oncologica.

[41]  E. Noordijk,et al.  Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  M. Cullen,et al.  Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. , 1988, British Journal of Cancer.

[43]  R. Folman,et al.  The role of chemotherapy in non-small cell lung cancer: the community perspective. , 1988, Seminars in oncology.

[44]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Drings.  Ifosfamide in the Treatment of Bronchial Carcinoma , 1987 .

[46]  B. O'Sullivan,et al.  The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. , 1986, British Journal of Cancer.

[47]  M. Kris,et al.  Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. , 1986, Cancer treatment reports.

[48]  L. Einhorn,et al.  Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Robert S. Fontana,et al.  Screening for Lung Cancer: Recent Experience in the United States , 1986 .

[50]  D. Ettinger,et al.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Sculier,et al.  Chemotherapy of non-small-cell lung cancer. , 1985, Seminars in oncology.

[52]  T. Demeester,et al.  Camp chemotherapy for metastatic non‐oat cell bronchogenic carcinoma. A 7‐year experience (1975–1981) with 160 patients , 1985, Cancer.

[53]  G. Anderson,et al.  Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group. , 1985, Seminars in oncology.

[54]  D. Finkelstein,et al.  Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  R. Stevenson,et al.  Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. , 1984, European journal of cancer & clinical oncology.

[56]  M. Bakowski,et al.  Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. , 1983, Cancer treatment reviews.

[57]  M Lavandier,et al.  Benefits of polychemotherapy in advanced non‐small‐cell bronchogenic carcinoma , 1982, Cancer.

[58]  Y. Park,et al.  Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. , 1981, Cancer treatment reports.

[59]  A. Brower.  Gastrointestinal series in patients with gallstones. , 1978, JAMA.

[60]  T. Demeester,et al.  Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). , 1978, JAMA.

[61]  J. O'fallon,et al.  Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. , 1977, Cancer treatment reports.

[62]  J. Peto,et al.  TREATMENT OF INOPERABLE CARCINOMA OF BRONCHUS , 1975, The Lancet.

[63]  F. Ellis,et al.  Comparison of treatment policies in inoperable bronchial carcinoma. , 1971, Lancet.

[64]  W. Weiss,et al.  The Philadelphia Pulmonary Neoplasm Research Project. , 1970, The Medical clinics of North America.